






FIG. 1

200**FIG. 2**

**FIG. 3**

400




FIG. 4




FIG. 5A

inferioparietal(lh,rh),superioparietal(lh,rh)
precuneus(lh,rh),lateraloccipital(lh,rh)
postcentral(lh),supramarginal(lh,rh)
middletemporal(lh),bankssts(lh)

- inferioparietal(lh)-hub




FIG. 5B

precentral(lh,rh),caudalmiddlefrontal(rh,lh)
paracental(rh,lh),superiorfrontal(rh)

- precentral(lh)-hub





FIG. 5C

RL: right lateral, RM: right medial

		Tau positivity status			
		Braak-0	Braak 1-2	Braak 3-4	Braak 5-6
N		131	13	48	120
Clinical Diagnosis	MCI	79	10	27	66
	mild AD	52	3	21	54
Gender	Female	65	8	25	59
	Male	66	5	23	61
ApoE4 status	Non-E4	82	3	11	40
	E4 carrier	49	10	37	80
Age*	Mean (SD)	71.2 (8.2)	72.6 (6.7)	75.6 (5.6)	70.6 (7.9)
BMI*	Mean (SD)	28.1 (4.0)	26.6 (4.0)	26.2 (3.3)	26.2 (3.8)
MMSE	Mean (SD)	25.6 (2.1)	26.5 (2.0)	25.9 (2.1)	25.4 (2.2)

FIG. 6




FIG. 7

Data used for deriving signatures*	% Overall Accuracy	
	For detecting <i><u>Tau positivity in Braak 3-6</u></i>	For further <i><u>discriminating Braak 3-4 and Braak 5-6</u></i>
Clinical (cognitive function)	76.0%	60.8%
pTau181 (plasma)	73.9%	66.8%
Clinical + pTau181	82.2%	67.6%
MRI	66.6%	68.1%
Clinical + MRI	73.7%	66.0%
pTau181 + MRI	75.0%	74.6%
Clinical + pTau181 + MRI	77.2%	75.8%

FIG. 8




FIG. 9A




FIG. 9B







FIG. 9C

**FIG. 10A**

**FIG. 10B**

**FIG. 10C**





FIG. 11A

**FIG. 11B**




FIG. 11C




FIG. 12A

Inferior parietal cortical thickness, grouped by tertiles




FIG. 12B

Clinical + Plasma pTau181




FIG. 13A




FIG. 13B

Clinical + Plasma pTau181 + MRI




FIG. 13C




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 15A




FIG. 15B

Data used for deriving signatures	% Accuracy			
	For detecting Tau positivity in Braak 3-6		For further discriminating Braak 3-4 and Braak 5-6	
	w/o APET	w APET	w/o APET	w APET
Clinical (cognitive func.)	76.0%	82.4%	60.8%	70.5%
pTau181 (plasma)	73.9%	86.2%	66.8%	72.0%
Clinical + pTau181	82.2%	83.4%	67.6%	74.2%
MRI	66.6%	81.0%	68.1%	73.9%
Clinical + MRI	73.7%	82.0%	66.0%	70.7%
pTau181 + MRI	75.0%	79.5%	74.6%	71.7%
Clinical + pTau181 + MRI	77.2%	81.7%	75.8%	69.6%

FIG. 16






FIG. 17A

**FIG. 17B**

Patient Characteristics		Training Set	Test Set
		N = 144	N = 98
Diagnosis	MCI; N (%)	93 (65%)	64 (65%)
	Mild AD; N (%)	51 (35%)	34 (35%)
Tau PET WCGM SUVR	Mean (SD)	1.37 (0.57)	1.41 (0.65)
	Quartiles (Q1, Q2, Q3)	(0.98, 1.13, 1.55)	(0.96, 1.10, 1.76)
Tau PET MTL SUVR	Mean (SD)	1.60 (0.61)	1.58 (0.61)
	Quartiles (Q1, Q2, Q3)	(1.04, 1.50, 1.97)	(1.05, 1.46, 1.98)
ApoE4 status	E4 homozygous; N (%)	13 (9%)	12 (12%)
	3R heterozygous; N (%)	68 (47%)	46 (47%)
	Non-E4; N (%)	63 (44%)	40 (41%)
Sex	Female; N (%)	69 (48%)	54 (55%)
	Male; N (%)	75 (52%)	44 (45%)
Age	Mean (SD)	72.7 (7.7)	70.5 (7.4)
Race	White; N (%)	133 (92%)	92 (94%)
	Non-White N (%)	11 (8%)	6 (6%)
MMSE	Mean (SD)	25.8 (2.2)	25.5 (2.1)

MMSE: minimal state examination; PET: positron emission tomography; SUVR: standardized uptake value ratio; WCGM: whole cortical grey matter; MTL; medial temporal lobe; SD, standard deviation.

FIG. 18A

**FIG. 18B**




FIG. 18C

Cross-validated R ² of the prediction model for each predictor type									
Region	pTau217R	Clinical	MRI	PET CL	other plasma biomarkers	pTau217R + Clinical	pTau217R + MRI	pTau217R + PET CL	pTau217R + other plasma biomarkers
Braak1	0.532	0.171	0.142	0.422	0.299	0.525	0.490	0.529	0.460
Braak2	0.514	0.186	0.118	0.395	0.307	0.490	0.457	0.507	0.418
Braak3	0.546	0.182	0.214	0.451	0.422	0.509	0.504	0.536	0.450
Braak4	0.639	0.161	0.231	0.426	0.428	0.599	0.605	0.620	0.577
Braak5	0.492	0.143	0.247	0.389	0.477	0.445	0.452	0.467	0.473
Braak6	0.236	0.067	0.185	0.276	0.348	0.186	0.212	0.211	0.198
Frontal	0.363	0.105	0.184	0.286	0.409	0.340	0.325	0.340	0.374
Occipital	0.338	0.114	0.240	0.324	0.392	0.293	0.323	0.316	0.282
Parietal	0.490	0.132	0.249	0.417	0.448	0.436	0.462	0.465	0.450
Lateral Temporal	0.635	0.153	0.230	0.429	0.413	0.593	0.606	0.619	0.567
Medial Temporal	0.582	0.180	0.158	0.431	0.329	0.567	0.534	0.576	0.494
WCGM	0.548	0.151	0.242	0.408	0.463	0.504	0.511	0.525	0.509

CL*: PET Centiloid; "Clinical": cognitive and functional assessment composites ADAS-Cog-14, MMSE, CDR-SB and ADCS-ADL, and all their sub-scores; "other plasma biomarkers": pTau181, GFAP, NfL, Aβ42/Aβ40.

Abbreviations: MRI: magnetic resonance imaging; PET: positron emission tomography; CL: Centiloid; GFAP: glial fibrillary acidic protein; NfL: neurofilament light chain; WCGM: whole cortical grey matter.

FIG. 19




FIG. 20A




FIG. 20B




FIG. 20C




FIG. 20D




FIG. 20E

Region	R ²	RMSE	MAE
Braak1	0.498	0.401	0.308
Braak2	0.381	0.466	0.370
Braak3	0.491	0.378	0.288
Braak4	0.585	0.414	0.310
Braak5	0.518	0.396	0.298
Braak6	0.378	0.327	0.238
Frontal	0.454	0.355	0.269
Occipital	0.387	0.471	0.320
Parietal	0.498	0.465	0.347
Lateral Temporal	0.577	0.428	0.324
Medial Temporal	0.511	0.391	0.299
WCGM	0.550	0.372	0.278

SUVr: standardized uptake value ratio; WCGM: whole cortical grey matter

FIG. 21

Region	R ²	RMSE	MAE
Braak1	0.502	0.399	0.308
Braak2	0.389	0.463	0.366
Braak3	0.483	0.382	0.291
Braak4	0.578	0.418	0.312
Braak5	0.511	0.399	0.297
Braak6	0.362	0.332	0.241
Frontal	0.444	0.358	0.270
Occipital	0.376	0.475	0.322
Parietal	0.492	0.467	0.348
Lateral Temporal	0.570	0.431	0.324
Medial Temporal	0.512	0.391	0.297
WCGM	0.544	0.375	0.278

FIG. 22

Region	R ²	RMSE	MAE
Braak1	0.380	0.448	0.351
Braak2	0.260	0.512	0.412
Braak3	0.387	0.420	0.324
Braak4	0.486	0.459	0.351
Braak5	0.459	0.418	0.312
Braak6	0.334	0.342	0.241
Frontal	0.419	0.364	0.278
Occipital	0.349	0.486	0.343
Parietal	0.425	0.496	0.368
Lateral Temporal	0.488	0.468	0.355
Medial Temporal	0.385	0.438	0.334
WCGM	0.472	0.403	0.301

FIG. 23




FIG. 24A




FIG. 24B




FIG. 25A




FIG. 25B




FIG. 25C




FIG. 25D




FIG. 26A




FIG. 26B




FIG. 26C




FIG. 26D




FIG. 26E




FIG. 26F

Regions	Tau positivity threshold (SUVR)	Quartiles of observed SUVR	Upper limit of SUVR prediction (95% CI)
Braak1	1.286	(1.16, 1.73, 2.24)	2.21 (2.06, 2.35)
Braak2	1.078	(0.89, 1.28, 1.83)	1.63 (1.38, 1.88)
Braak3	1.195	(1.04, 1.33, 1.85)	1.87 (1.72, 2.02)
Braak4	1.150	(0.99, 1.18, 2.02)	2.21 (1.94, 2.47)
Braak5	1.114	(0.95, 1.09, 1.52)	2.09 (1.65, 2.54)
Braak6	1.111	(0.89, 0.98, 1.14)	1.42 (1.32, 1.52)
Frontal	1.119	(0.9, 1.02, 1.21)	1.68 (1.4, 1.96)
Occipital	1.200	(1.06, 1.17, 1.64)	1.77 (1.65, 1.89)
Parietal	1.131	(0.94, 1.07, 1.63)	2.8 (1.72, 2.45)
Lateral Temporal	1.175	(1.03, 1.25, 2.13)	2.3 (2.04, 256)
Medial Temporal	1.173	(1.05, 1.48, 1.97)	2.04 (1.91, 2.17)
WCGM	1.126	(0.98, 1.12, 1.68)	2.1 (1.7, 2.5)

SUVR: standardized uptake value ratio; CI: confidence interval; WCGM: whole cortical grey matter

FIG. 27

Region	Tau positivity prediction			Tau status prediction at SUVR = 1.5		
	AUROC	Sensitivity	Specificity	AUROC	Sensitivity	Specificity
Braak1	0.93 (0.88, 0.98)	0.88 (0.8, 0.95)	0.76 (0.61, 0.91)	0.92 (0.86, 0.97)	0.84 (0.74, 0.93)	0.85 (0.73, 0.95)
Braak2	0.91 (0.85, 0.97)	0.82 (0.73, 0.9)	0.81 (0.67, 0.92)	0.79 (0.71, 0.88)	0.65 (0.5, 0.8)	0.76 (0.65, 0.86)
Braak3	0.91 (0.86, 0.97)	0.86 (0.78, 0.95)	0.8 (0.68, 0.93)	0.86 (0.79, 0.94)	0.79 (0.67, 0.92)	0.81 (0.71, 0.9)
Braak4	0.95 (0.91, 1)	0.94 (0.86, 1)	0.76 (0.63, 0.86)	0.87 (0.8, 0.95)	0.83 (0.69, 0.94)	0.81 (0.69, 0.9)
Braak5	0.89 (0.82, 0.96)	0.91 (0.82, 0.98)	0.72 (0.58, 0.83)	0.84 (0.75, 0.93)	0.63 (0.44, 0.81)	0.83 (0.73, 0.92)
Braak6	0.85 (0.76, 0.93)	0.81 (0.65, 0.94)	0.73 (0.63, 0.84)	0.84 (0.69, 1)	0.38 (0.15, 0.62)	1 (1, 1)
Frontal	0.84 (0.75, 0.93)	0.82 (0.67, 0.94)	0.72 (0.62, 0.83)	0.85 (0.75, 0.95)	0.41 (0.23, 0.65)	0.93 (0.86, 0.98)
Occipital	0.86 (0.78, 0.94)	0.87 (0.76, 0.96)	0.68 (0.55, 0.79)	0.88 (0.8, 0.95)	0.78 (0.63, 0.91)	0.83 (0.74, 0.92)
Parietal	0.87 (0.79, 0.94)	0.9 (0.8, 0.98)	0.7 (0.58, 0.81)	0.85 (0.77, 0.94)	0.7 (0.53, 0.87)	0.82 (0.72, 0.91)
Lateral Temporal	0.92 (0.86, 0.97)	0.87 (0.78, 0.94)	0.75 (0.61, 0.86)	0.87 (0.8, 0.95)	0.85 (0.74, 0.95)	0.76 (0.64, 0.86)
Medial Temporal	0.9 (0.84, 0.96)	0.87 (0.79, 0.95)	0.69 (0.51, 0.83)	0.9 (0.84, 0.96)	0.88 (0.77, 0.96)	0.78 (0.66, 0.88)
WCGM	0.92 (0.86, 0.97)	0.91 (0.83, 0.98)	0.73 (0.6, 0.85)	0.88 (0.81, 0.96)	0.73 (0.58, 0.88)	0.85 (0.75, 0.92)

SUVR: standardized uptake value ratio; WCGM: whole cortical grey matter

FIG. 28




FIG. 29A




FIG. 29B




FIG. 29C




FIG. 29D

Region	SUVR Threshold	Age			Sex			ApoE4		
		<70	>=70	p-value	Male	Female	p-value	No	Yes	p-value
MTL	1.5	94.6 (87.0, 100.0)	87.3 (77.5, 97.1)	0.252	90.5 (82.1, 98.8)	89.9 (80.2, 99.6)	0.932	92.7 (84.0, 100.0)	87.3 (78.1, 96.6)	0.411
	1.73 (TP)	99.1 (97.3, 100.0)	82.5 (71.3, 93.7)	0.006	86.7 (75.9, 97.6)	93.6 (97.6, 99.5)	0.280	87.2 (74.0, 100.0)	88.0 (79.2, 96.9)	0.923
WCGM	1.5	97.7 (94.1, 100.0)	78.9 (64.7, 93.0)	0.014	86.2 (73.2, 99.3)	90.7 (82.2, 99.1)	0.576	88.9 (74.7, 100.0)	87.4 (78.7, 96.1)	0.865
	1.126 (TP)	97.1 (93.3, 100.0)	87.2 (77.5, 97.0)	0.068	87.8 (76.8, 98.8)	95.4 (90.4, 100.0)	0.222	90.6 (79.2, 100.0)	91.4 (84.6, 98.3)	0.906

Standardized uptake value ratio: MTL: media temporal lobe; WCGM: whole cortical grey matter

FIG. 30

Region	FNR	SUVR Threshold	
		Tau positivity	SUVR = 1.5
MTL	0.2	88.6% (60.0%, 97.1%)	84.0% (70.0%, 96.0%)
	0.1	62.9% (42.9%, 91.4%)	76.0% (51.8%, 90.0%)
	0.05	54.3% (14.3%, 77.1%)	68.0% (40.0%, 86.0%)
WCGM	0.2	88.5% (71.2%, 98.1%)	81.5% (69.2%, 93.8%)
	0.1	75.0% (45.9%, 92.3%)	75.4% (30.8%, 89.2%)
	0.05	65.4% (5.8%, 86.5%)	43.6% (3.1%, 84.6%)

FIG. 31




FIG. 32A




FIG. 32B

Patient characteristics	Training cohort N=904	Validation cohort 1 N=622	Validation cohort 2 N=357
Diagnosis			
CUI; N (%)	620(68%)	622(100%)	0
MCI; N (%)	186(21%)	0	320(90%)
Mild dementia; N (%)	98(11%)	0	37(10%)
Amyloid PET Centiloid			
Mean (SD)	39.6(43.7)	22.9(32.1)	37.5(47.8)
Quartiles (Q1, Q2, Q3)	(2.24, 74)	(-0.4, 8, 42)	(-1, 18, 73)
Sex*			
Female; N (%)	546(60%)	417(67%)	192(54%)
Male; N (%)	358(40%)	205(33%)	165(46%)
APOE ε4 status*			
ε4 homozygous; N (%)	92(10%)	53(8%)	19(5%)
ε4 heterozygous; N (%)	378(42%)	248(40%)	114(32%)
Non-ε4; N (%)	434(48%)	321(52%)	224(63%)
Age*			
Mean (SD)	69.1 (6.7)	67.7(6.2)	71.5(7.3)
Education*			
Mean (SD)	16.1 (3.1)	16.2(3.0)	13.3(3.6)
Race			
White; N (%)	801(89%)	569(91%)	324(91%)
Non-White; N (%)	103(11%)	53(9%)	33(9%)
MMSE			
Mean (SD)	28.0(2.1)	29.0(1.0)	26.6(1.7)

FIG. 33

Validation cohort	Models	SGB			BLLR		
		R^2	MAE	RMSE	R^2	MAE	RMSE
VC-1	A β 42/A β 40	0.30	22.13	28.57	0.28	23.78	29.44
	pTau217R	0.63*	14.21	20.19	0.56	17.00	21.89
	pTau217R and A β 42/A β 40	0.65*	13.66	19.61	0.60	16.17	20.82
VC-2	A β 42/40	0.16	34.71	44.77	0.16	36.59	46.46
	pTau217R	0.66*	20.41	28.09	0.53	25.78	33.00
	pTau217R and A β 42/A β 40	0.63*	20.73	29.23	0.51	24.75	33.30

FIG. 34





FIG. 35A

**FIG. 35B**






FIG. 35C

**FIG. 36A**

**FIG. 36B**





FIG. 36C


CL status	Models	VC-1			VC-2		
		% AUROC	% Sensitivity	% Specificity	% AUROC	% Sensitivity	% Specificity
CL > 15	AP _{642/A₃₄₀}	83.5 (80.3, 86.7)	92.4 (89.2, 95.6)	48.2 (43.4, 53.4)	78.1 (73.2, 83)	90.9 (86.6, 94.6)	51.5 (43.9, 59.1)
	pTau217R	89.9 (87.4, 92.5)	82.1 (77.3, 86.5)	84.5 (80.9, 88.1)	91.6 (88.6, 94.6)	88.7 (83.9, 93)	83.6 (77.8, 88.9)
	pTau217R + AP _{642/A₃₄₀}	92.7 (90.6, 94.8)	86.5 (82.1, 90.4)	85.4 (81.4, 88.9)	92.9 (90.2, 95.7)	90.9 (86.6, 94.6)	77.8 (71.3, 83.6)
CL > 30	AP _{642/A₃₄₀}	83.5 (80.2, 86.7)	84.5 (79.1, 89.3)	68.7 (64.4, 72.9)	74.4 (69.2, 79.5)	85.3 (79.3, 90.7)	57 (50.2, 63.8)
	pTau217R	92.1 (89.6, 94.6)	82.9 (77.5, 88.2)	87.4 (84.1, 90.3)	92.7 (89.8, 95.6)	90 (84.7, 94.7)	85.5 (80.7, 90.3)
	pTau217R + AP _{642/A₃₄₀}	94.5 (92.9, 96.2)	81.3 (75.4, 86.6)	89.9 (87.1, 92.6)	93.2 (90.5, 95.9)	92 (87.3, 96)	80.2 (74.9, 85.5)
CL > 40	AP _{642/A₃₄₀}	81.9 (76.5, 85.4)	71.9 (65, 78.8)	76.8 (72.7, 80.5)	72.6 (67.4, 77.9)	74.6 (67.6, 81.7)	64.2 (57.7, 70.2)
	pTau217R	93.2 (90.8, 95.6)	82.5 (76.9, 88.8)	90.9 (88.1, 93.3)	93.2 (90.4, 96)	89.4 (83.8, 94.4)	88.4 (83.7, 92.6)
	pTau217R + AP _{642/A₃₄₀}	94.7 (93, 96.3)	83.8 (78.1, 89.4)	92 (89.4, 94.4)	92.8 (90, 95.6)	87.3 (81.7, 92.3)	88.4 (83.7, 92.6)
CL > 50	AP _{642/A₃₄₀}	80.6 (76.9, 84.3)	50.7 (41.9, 58.8)	84.8 (81.3, 87.7)	71 (65.6, 76.3)	63.6 (55.3, 72)	69.3 (63.1, 75.6)
	pTau217R	93.9 (91.9, 95.9)	78.7 (71.3, 85.3)	93 (90.7, 95.1)	93.8 (91.1, 96.4)	84.1 (77.3, 90.2)	91.1 (87.1, 94.7)
	pTau217R + AP _{642/A₃₄₀}	94 (92.1, 95.8)	77.2 (70.6, 84.6)	92.8 (90.5, 94.9)	92.8 (89.9, 95.6)	80.3 (73.5, 87.1)	89.3 (85.3, 92.9)
CL > 70	AP _{642/A₃₄₀}	77.9 (72.9, 82.9)	15.7 (7.1, 24.3)	95.8 (94.2, 97.5)	68.6 (63, 74.3)	22.9 (14.6, 31.3)	85.8 (81.2, 90)
	pTau217R	92.1 (89.3, 94.8)	58.6 (47.1, 70)	93.5 (91.3, 95.3)	93.8 (91.4, 96.1)	76 (67.7, 84.4)	91.2 (87.7, 94.3)
	pTau217R + AP _{642/A₃₄₀}	91.9 (89.4, 94.4)	57.1 (45.7, 68.6)	92.4 (90.2, 94.6)	92.9 (90.3, 95.5)	74 (64.6, 82.3)	90.8 (87.4, 93.9)
CL > 90	AP _{642/A₃₄₀}	77.5 (71.84.1)	0 (0, 0)	99.7 (99.1, 100)	68.3 (62.4, 74.1)	1.4 (0, 4.1)	97.9 (96.1, 99.3)
	pTau217R	92.6 (88.2, 97)	41.2 (26.5, 58.8)	97.6 (96.3, 98.8)	90.6 (87.6, 93.7)	42.5 (31.5, 53.4)	94.4 (91.5, 96.8)
	pTau217R + AP _{642/A₃₄₀}	92.8 (89.3, 96.3)	35.3 (20.6, 50)	98 (96.6, 99)	89.3 (85.9, 92.7)	27.4 (17.8, 37)	95.8 (93.7, 97.9)

FIG. 37



--- Aβ42/Aβ40, AUROC=83.5%
... pTau217R, AUROC=89.9%
- . pTau217R & Aβ42/Aβ40, AUROC=92.7%

FIG. 38A



--- Aβ42/Aβ40, AUROC=83.5%
... pTau217R, AUROC=92.1%
- . pTau217R & Aβ42/Aβ40, AUROC=94.5%

FIG. 38B




FIG. 38C




FIG. 38D




FIG. 38E




FIG. 38F




FIG. 38G




FIG. 38H




FIG. 39

		Amyloid Negative	Low Amyloid	High Amyloid
Amyloid-PET CL criteria		CL < 20	CL 20-40	CL > 40
N (%)		784 (63%)	132 (11%)	320 (26%)
Gender	Female; N (%)	516 (66%)	94 (71%)	205 (64%)
	Male; N (%)	268 (34%)	38 (29%)	115 (36%)
Race	White; N (%)	719 (92%)	124 (94%)	297 (93%)
	Black/Hispanic; N (%)	18 (2%)	-	-
	Other; N (%)	27 (3%)	6 (5%)	15 (5%)
ApoE	non-E4; N (%)	525 (67%)	46 (35%)	67 (21%)
	E4 heterozygous; N (%)	229 (29%)	67 (51%)	197 (61%)
	E4 homozygous; N (%)	30 (4%)	19 (14%)	56 (18%)
Age	Mean (SD)	66.8 (6.1)	68.7 (5.5)	70.1 (5.5)
BMI	Mean (SD)	28.7 (5.9)	28.2 (5.9)	27.4 (5.5)
MMSE	Mean (SD)	29.0 (1.0)	29.1 (1.1)	29.0 (1.0)

FIG. 40




FIG. 41A




FIG. 41B




FIG. 42




FIG. 43

		Predicted Amyloid Status			
Amyloid-PET CL criteria		Screen Fail	CL<20	CL 20-40	CL>40
N (%)		26 (20%)	70 (50%)	22 (15%)	20 (14%)
Age	Mean (SD)	68.2 (8.4)	70.1 (6.4)	71.4 (4.6)	73.8 (3.9)
Gender	Female; N (%)	9 (35%)	57 (81%)	19 (86%)	14 (70%)
	Male; N (%)	3 (12%)	13 (19%)	3 (14%)	6 (30%)
Race	White; N (%)	4 (15%)	45 (64%)	17 (77%)	16 (80%)
	Black; N (%)	5 (19%)	19 (27%)	3 (14%)	2 (10%)
	Hispanic; N (%)	1 (4%)	6 (9%)	2 (9%)	-
	Other; N (%)	3 (12%)	-	-	2 (10%)

FIG. 44